Ocugen Inc logo

OCGN - Ocugen Inc Share Price

$7.23 0.5  7.7%

Last Trade - 4:06pm

Market Cap £918.0m
Enterprise Value £902.0m
Revenue £31.0k
Position in Universe 2615th / 6848
Unlock OCGN Revenue
Relative Strength (%)
1m -35.5%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -64.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.043 452.3 858
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, OcugenInc revenues increased from $0K to $43K. Net lossapplicable to common stockholders increased 70% to $34.4M.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Higher net loss reflects Selling, general andadministrative - Ba increase of 33% to $7.6M (expense),Interest income decrease of 12% to $1K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for OCGN
Graphical History


OCGN Revenue Unlock OCGN Revenue

Net Income

OCGN Net Income Unlock OCGN Revenue

Normalised EPS

OCGN Normalised EPS Unlock OCGN Revenue

PE Ratio Range

OCGN PE Ratio Range Unlock OCGN Revenue

Dividend Yield Range

OCGN Dividend Yield Range Unlock OCGN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
OCGN EPS Forecasts Unlock OCGN Revenue
Profile Summary

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated July 14, 2006
Public Since December 3, 2014
No. of Shareholders: 21
No. of Employees: 15
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 188,088,860
Free Float (0.0%)
Eligible for
OCGN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for OCGN
Upcoming Events for OCGN
Thursday 6th May, 2021 Estimate
Q1 2021 Ocugen Inc Earnings Release
Thursday 12th August, 2021 Estimate
Q2 2021 Ocugen Inc Earnings Release
Frequently Asked Questions for Ocugen Inc
What is the Ocugen Inc share price?

As of 4:06pm, shares in Ocugen Inc are trading at $7.23, giving the company a market capitalisation of £918.0m. This share price information is delayed by 15 minutes.

How has the Ocugen Inc share price performed this year?

Shares in Ocugen Inc are currently trading at $7.23 and the price has moved by 2.02k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ocugen Inc price has moved by 1.36k% over the past year.

What are the analyst and broker recommendations for Ocugen Inc?

Of the analysts with advisory recommendations for Ocugen Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Ocugen Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Ocugen Inc next release its financial results?

Ocugen Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Ocugen Inc dividend yield?

Ocugen Inc does not currently pay a dividend.

Does Ocugen Inc pay a dividend?

Ocugen Inc does not currently pay a dividend.

When does Ocugen Inc next pay dividends?

Ocugen Inc does not currently pay a dividend.

How do I buy Ocugen Inc shares?

To buy shares in Ocugen Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Ocugen Inc?

Shares in Ocugen Inc are currently trading at $7.23, giving the company a market capitalisation of £918.0m.

Where are Ocugen Inc shares listed? Where are Ocugen Inc shares listed?

Here are the trading details for Ocugen Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: OCGN
What kind of share is Ocugen Inc?

Based on an overall assessment of its quality, value and momentum, Ocugen Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Ocugen Inc share price forecast 2021?

Shares in Ocugen Inc are currently priced at $7.23. At that level they are trading at 34.13% discount to the analyst consensus target price of 0.00.

Analysts covering Ocugen Inc currently have a consensus Earnings Per Share (EPS) forecast of 2.195 for the next financial year.

How can I tell whether the Ocugen Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ocugen Inc. Over the past six months, the relative strength of its shares against the market has been 1.64k%. At the current price of $7.23, shares in Ocugen Inc are trading at 0.160k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Ocugen Inc PE Ratio?

We were not able to find PE ratio data for Ocugen Inc.

Who are the key directors of Ocugen Inc?

Ocugen Inc's management team is headed by:

Shankar Musunuri - CHM
Vijay Tammara - SVP
Kelly Beck - VPR
Sanjay Subramanian - CFO
Uday Kompella - IND
Ramesh Kumar - IND
Manish Potti - IND
Kirsten Castillo - IND
Prabhavathi Fernandes - IND
Who are the major shareholders of Ocugen Inc?

Here are the top five shareholders of Ocugen Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.82% (9.07m shares)
SPDR S&P Biotech ETF Mutual Fund
Percentage owned: 2.64% (4.96m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 2.32% (4.36m shares)
Vanguard Extended Market Index Fund Mutual Fund
Percentage owned: 1.23% (2.31m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 1.18% (2.22m shares)
Similar to OCGN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.